Polycystic kidney
Also known as: Kidney, Renal, Nephric, Nephron
Methodology & AI Transparency ⓘ
Polycystic kidney Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Chronic Kidney Disease & Electrolytes diagnostic criteria (Q61.02), workup for Polycystic kidney (also termed Kidney or Renal) integrates serial eGFR (creatinine in Polycystic kidney (Q61.02: + cystatin C)) with evidence-graded therapy tailored to Urine Albumin-to-Creatinine Ratio in Polycystic kidney (Q61.02: (uACR)) response.
- 2 Real-world patient consensus: Synonyms for Polycystic kidney (Q61.02): Kidney, Renal, Nephric (Kidney & Renal).
- 3 Typical cash cost range: Primary evaluation for Polycystic kidney incorporates serial eGFR (creatinine in Polycystic kidney (Q61.02: + cystatin C)) and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Polycystic kidney monitoring tracks Urine Albumin-to-Creatinine Ratio in Polycystic kidney (Q61.02: (uACR)) toward < 15 mg/g (< 30 mg/g normal) (Q61.02).
Ask our AI Specialists anything about Polycystic kidney
What Is Polycystic kidney?
Under Chronic Kidney Disease & Electrolytes diagnostic criteria (Q61.02), workup for Polycystic kidney (also termed Kidney or Renal) integrates serial eGFR (creatinine in Polycystic kidney (Q61.02: + cystatin C)) with evidence-graded therapy tailored to Urine Albumin-to-Creatinine Ratio in Polycystic kidney (Q61.02: (uACR)) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Polycystic kidney (Q61.02) center on glomerular capillary hyperfiltration in Polycystic kidney (Q61.02: barotrauma). targeted kidney & renal interventions aim to normalize Urine Albumin-to-Creatinine Ratio in Polycystic kidney (Q61.02: (uACR)).
Common Symptoms & Clinical Signs
- • Presentation of Polycystic kidney (Q61.02): asymptomatic decline in in Polycystic kidney (Q61.02: eGFR or persistent)
- • Secondary Polycystic kidney clinical sign: fluid retention in in Polycystic kidney (Q61.02: ankles, hands, or)
- • Symptom flares in Polycystic kidney correlating with Urine Albumin-to-Creatinine Ratio in Polycystic kidney (Q61.02: (uACR)) deviation outside < 15 mg/g (< 30 mg/g normal) (Q61.02)
- • Functional kidney & renal impact requiring serial eGFR (creatinine in Polycystic kidney (Q61.02: + cystatin C)) evaluation (Q61.02)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Polycystic kidney Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q61.02 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Polycystic kidney (Q61.02: (uACR)) | < 15 mg/g (< 30 mg/g normal) (Q61.02) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Polycystic kidney (Q61.02: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (Q61.02) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Polycystic kidney (Q61.02: Cystatin C)) | >= 90 mL/min/1.73m2 (Q61.02) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Polycystic kidney
Treatment selection for Polycystic kidney depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Polycystic kidney)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of N -Acetylcysteine in Polycystic Ovary Syndrome: Systematic Review and: What a 2,515-Participant Study Found NAC had a major effect on progesterone, endometrial thickness, and LH levels in women with PCOS. Nutrients • 2025-01-14 • Meta-Analysis | N = 2,515 | 99/100 | PMID 39861414 ↗ |
| New Insights on Effectiveness of myoinositol for polycystic ovary: What a 573-Participant Study Found Based on current evidence, myoinositol may be recommended for the treatment of PCOS with insulin resistance, as well as for improving symptoms caused by decreased estrogen in PCOS. Endocrine • 2018-01-15 • Meta-Analysis | N = 573 | 97/100 | PMID 29052180 ↗ |
| New Insights on Impact of subclinical hypothyroidism on core reproductive hormones and ovarian: What a 3,114-Participant Study Found Current evidence shows no significant differences in FSH, LH, estradiol, or total testosterone levels between SCH and euthyroid PCOS controls, while the evidence for prolactin. Frontiers in endocrinology • 2026-01-15 • Meta-Analysis | N = 3,114 | 94/100 | PMID 42798498 ↗ |
| New Insights on Reproductive hormone characteristics of obese Chinese patients with polycystic: What a 4,554-Participant Study Found Conversely, they exhibited significantly higher testosterone (T) ( p = 0.001) levels. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology • 2025-12-15 • Meta-Analysis | N = 4,554 | 94/100 | PMID 40287875 ↗ |
| New Insights on Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use: What a 257-Participant Study Found In participants with T2D and CKD, consistent benefits of semaglutide on major kidney outcomes, MACE, and all-cause mortality were observed regardless of baseline MRA use. Diabetes care • 2025-11-01 • Randomized Controlled Trial | N = 257 | 93/100 | PMID 40730031 ↗ |
Polycystic kidney Patient Community & “People Like Me” Threads
Filter Polycystic kidney community threads and patient logs by age, biological sex, dosage, and treatment duration.